Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
M2951 (Evobrutinib) in Rheumatoid Arthritis
NCT02784106Phase 2Completed
- Sponsor
- EMD Serono
- Start
- Jul 2016
- Primary completion
- Apr 2017
- Modality
- Small Molecules
- Countries
- 2
01
Overview
A Phase 2 trial of evobrutinib in rheumatoid arthritis (RA), sponsored by EMD Serono. Started Jul 2016; status: completed.
02
Drugs
evobrutinib
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT02784106.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02784106.